U.K. trial hold for Sarepta's SRP-4045 combo

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said it halted dosing at U.K. study sites in the Phase III ESSENCE trial evaluating golodirsen (SRP-4053) and casimersen (SRP-4045) to treat Duchenne muscular dystrophy.

In a statement,

Read the full 314 word article

User Sign In